Similar Search Results

Adverse effects of patent pooling on product development and commercialization

Jeitschko, Thomas D.; Zhang, Nanyun - In: The B.E. journal of theoretical economics 14 (2014) 1, pp. 27-57

Persistent link: https://www.econbiz.de/10010417576

Neglected dimension of the inventive step as applied to pharmaceutical and biotechnological products : the case of Sri Lanka's patent law

Fernando, Ruwan - 2023

-Related Aspects of Intellectual Property Rights (TRIPS) and its biotechnology/pharmaceutical policy guidelines. This approach that is …

Persistent link: https://www.econbiz.de/10014324836

The US Patent Holdings of Homegrown Indian Biotech and Pharma Companies

Sundaramoorthy, Sriramkumar; Yerram, Chandra Bindu; … - 2016

We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one snapshot of the biotech industry in India today. It...

Persistent link: https://www.econbiz.de/10014129813

Creating knowledge assets under biocapitalism : analyzing China's biomedical industry and its patent networks

Zhou, Yu; Sun, Feixiang - In: Economic geography 98 (2022) 5, pp. 411-437

Persistent link: https://www.econbiz.de/10013484806

What about Know-How : Heightened Obviousness and Lowered Disclosure is Not a Panacea to the American Patent System for Biotechnology Medication and Pharmaceutical Inventions in the...

Su, Yi-Chen - 2013

In KSR International, the U.S. Supreme Court rejected the Federal Circuit's rigid application of “teaching, suggestion, or motivation” test (TSM test), and replaced it with an “expansive and flexible” approach, in determining the question of obviousness. Nevertheless, an expansive and...

Persistent link: https://www.econbiz.de/10013095605

The patentability of biotechnology in Europe

Mareüil-Villette, Caroline de; Raets, David - In: Patents in Europe : helping business compete in the … 3 (2008), pp. 17-20

Persistent link: https://www.econbiz.de/10003726303

Délimiter le marché de la santé et faire le droit du vivant : le rôle des oppositions juridiques aux brevets sur les gènes en Europe

Cassier, Maurice - In: Revue d'économie industrielle 120 (2007) 4, pp. 155-174

Persistent link: https://www.econbiz.de/10003626973

Reach-through patent claims in biotechnology : an analysis of the examination practices of the United States, European and Japanese patent offices

Lim, Amanda S. Y. (contributor); … - 2005

Persistent link: https://www.econbiz.de/10003217452

Comparative Analysis of Patenting Biotechnology Inventions in the U.S., Europe, Japan and China

Han, Weiwei - 2014

biotechnology inventions in the U.S., Europe, Japan and China. Doctrines and practice regarding patent eligibility, utility, novelty …Biotechnology has been developing at a dramatic pace. The success story of modern biotechnology industry is closely … linked with the evolution of modern patent law and patents are pillars of biotechnology industry. The context for patenting …

Persistent link: https://www.econbiz.de/10013064468

Patent politics : life forms, markets, and the public interest in the United States and Europe

Parthasarathy, Shobita - 2017

over patents on animals, human embryonic stem cells, human genes, and plants in the United States and Europe, she shows how …. And through these debates, the United States and Europe are developing very different approaches to patent and innovation … governance. Not just the first comprehensive look at the controversies swirling around biotechnology patents, Patent Politics is …

Persistent link: https://www.econbiz.de/10011932663

1
2
3
4
5
6
7
8
9
10
Next
Last